Filament Health Corp. (TSE:FH) has released an update.
Filament Health Corp., a clinical-stage natural psychedelic drug development company, has secured C$1.0 million in bridge financing. The deal involved Negev Capital Fund One, LP exercising warrants and converting a convertible note into common shares at a reduced price, alongside a share purchase by CEO Benjamin Lightburn. The financing, pending regulatory approval, aims to support the company’s commitment to advancing its clinical development programs.
For further insights into TSE:FH stock, check out TipRanks’ Stock Analysis page.